ADMA Biologics, Inc. (ADMA) Stock
ADMA Key Statistics
About ADMA Biologics, Inc.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
CEO: Adam S. Grossman. Company website
ADMA — Frequently Asked Questions
What is the ADMA stock price today?
ADMA Biologics, Inc. (ADMA) trades at $9.11, up 1.79% on the day, as of Sep 20, 2026 14:57 UTC.
What is ADMA Biologics, Inc.'s market cap?
ADMA Biologics, Inc. has a market capitalisation of $2.11B, calculated from the live ADMA share price and shares outstanding.
What is the P/E ratio of ADMA?
ADMA trades at a trailing P/E of 13.01, from earnings per share of $0.70 over the last twelve months.
How much revenue does ADMA Biologics, Inc. make?
ADMA Biologics, Inc. generated revenue of $512.28M over the trailing twelve months, which puts the stock at 4.12 times sales.
What is the 52-week range for ADMA?
ADMA has traded between $7.21 and $20.46 over the past 52 weeks, and the last price is 55.5% below that high.
Is ADMA Biologics, Inc. profitable?
Yes. ADMA Biologics, Inc. keeps 32.98% of revenue as net income over the trailing twelve months.
What is the analyst price target for ADMA?
Wall Street analysts rate ADMA Buy, with an average price target of $18.67, 104.9% above the current price.
What sector is ADMA Biologics, Inc. in?
ADMA Biologics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of ADMA Biologics, Inc.?
Adam S. Grossman is the chief executive of ADMA Biologics, Inc., which employs 644 people.
Where can I track ADMA in real time?
QFI Terminal shows ADMA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ADMA live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ADMA in Terminal See plans